LogicBio Therapeutics Q1 2025 Earnings Report

LogicBio Therapeutics EPS Results

• Actual EPS: -$0.27
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

LogicBio Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

LogicBio Therapeutics Announcement Details

• Quarter: Q1 2025
• Date: 5/9/2025
• Time: After Market Closes
• Conference Call Date: Friday, May 9, 2025
• Conference Call Time: 5:00PM ET

LogicBio Therapeutics (NASDAQ:LOGC), a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

LogicBio Therapeutics Q1 2025 Earnings Call Transcript

[Operator]

Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to ContextLogic's First Quarter twenty twenty five Earnings Conference Call. At this time, participants are in a listen only mode and there will not be a question and answer session at the conclusion of today's call. However, a recording and transcript will be made available online and management will make themselves available to the investor community over the coming weeks. Except for historical information, the matters discussed during this call may include forward looking statements within the meaning of the applicable U.

[Operator]

S. Securities legislation. Forward looking statements involve known and unknown risks and uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from estimated future results, performance or achievements expressed or implied by those forward looking statements. All forward looking statements reflect each of the company's current views with respect to future events and are subject to risks and uncertainties and assumptions have been made in drawing the conclusions included in such forward looking statements. All statements other than historical facts are forward looking statements.

[Operator]

Actual results could differ materially, and the company undertakes no obligation to update any such forward looking statements. Please also note that the past performance is not a guarantee of future results. During this call, there will be reference to certain non IFRS and non GAAP financial measures, which should not be considered in isolation from or as a substitute for measures prepared in accordance with international financial reporting standards or generally accepted accounting principles. As a reminder, all figures, unless otherwise noted, will be in U. S.

[Operator]

Dollars. I will now turn the call over to the host of today's call, Rishi Bajaj, CEO of ContactsLogic. Mr. Bajaj, you may begin.

[Speaker 1]

Good afternoon. I would like to briefly highlight our operating results for the quarter ended 03/31/2025. In Q1 twenty twenty five, we raised $75,000,000 in cash from BC Partners through an investment in a subsidiary of the company, which also included a company option for an additional $75,000,000 that we can call to help fund the future acquisition. We incurred $6,000,000 of G and A expenses, which include $2,000,000 of expenses related to the evaluation of perceived potential transactions, including the BC Partners strategic investment. We incurred $3,000,000 of costs directly related to the BC Partners investment, which are recorded as stock issuance costs.

[Speaker 1]

This implies that we expended approximately $5,000,000 of cash on transaction related costs during the quarter. Our cash expenses were offset by interest income of approximately $2,000,000 We closed the quarter with $222,000,000 of cash, cash equivalents and marketable securities, which includes the $75,000,000 we raised from BC Partners. This compares to $149,000,000 at the end of fiscal year twenty twenty four. As evidenced by our limited cash burn, we are committed to keeping cash expenses low in order to leave us with the most cash possible to grow and create both organically and through acquisition a strong and durable business. Since BC Partners closed the strategic investment in ContentLogic, Ted Goldthorpe and the BC Partners team have worked daily with ContentLogic to identify growth and acquisition opportunities.

[Speaker 1]

We have been overwhelmed by the effort from BC Partners expanding our pipeline of opportunities and enhancing our capabilities. And we're extremely encouraged by the receptiveness of our potential partners as well as the quality of inbound outreach. Ted and I are excited to share more with you in the coming quarters as we make progress along our growth strategy.

[Operator]

Ladies and gentlemen, this does conclude today's conference call. Again, thank you very much for joining us today. You may all disconnect and have a wonderful day. Goodbye.